1. Vardiman JW, Harris NL, Banning R: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292, 2002.

2. Bennett JM, Catovsk D, Daniel TM, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746, 1994.

3. Onida F, Beran M: Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 3:218, 2004.

4. Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomono-cytic leukemia: a retrospective analysis of 213 patients. Blood 99:840, 2002.

5. Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481, 2002.

6. Magnusson MK, Meade KE, Nakamura R, et al.: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100:1088, 2002.

7. Anastasiadou E, Schwaller J: Role of constitutively activated protein tyrosine kinases in malignant myeloprolif-erative disorders: an update. Curr Opin Hematol 10:40, 2003.

8. Steer EJ, Cross NCP: Myeloproliferative disorders with translocation of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol 107:113, 2002.

9. Hellstrom-Lindberg E: Efficacy of erythropoetin in the myelodysplastic syndromes: a meta analysis of 205 patients from 17 studies. Br J Haematol 89:67, 1995.

10. Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP-16 in advanced chronic myelomonocytic leukemia. Blood 88:2480, 1996.

11. Greenberg BR, Reynolds RD, Charron CB, et al.: Treatment of myelodysplastic syndromes with daily oral idarubicin: a phase I—II study. Cancer 71:1989, 1993.

12. Lowenthal RM, Lambertenghi-Deliliers G: Oral idaru-bicin as treatment for advanced myelodysplastic syndrome. Haematologica 76:398, 1991.

13. Oscier DG, Worsley A, Hamblin T, et al.: Treatment of chronic myelomonocytic leukemia with low dose etoposide. Br J Haematol 72:468, 1989.

14. Doll DC, Kasper LM, Taetle R, et al.: Treatment with low-dose oral etoposide in patients with myelodysplas-tic syndromes. Leuk Res 22:9, 1998.

15. Tilman M, Saben A, Hakimian D, et al.: 2-chlorode-oxyadenosine (2-CDA) in the treatment of myelomonocytic leukemias. Proc Am Soc Clin Oncol 14:340a, 1995. Abstract 1022.

16. Krieger O, Uaspara H, Girschkofsky D, et al.: 2-Chloro-deoxadenosine (2-CDA) in the therapy of high risk CMML. Br J Haematol 96(suppl 2):231, 1996. Abstract 867.

17. Seymour J, Cortes J.: Chronic myelomonocytic leukemia. In: Talpaz M, Kantarjian H (eds.) Medical Management of Chronic Myelogenous Leukemia. New York: Marcel Dekker, Inc; 1999:43.

18. Beran M, Estey E, O'Brien S, et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomono-cytic leukemia. J Clin Oncol 17:2819, 1999.

19. Beran M, Kantarjian H, O'Brien S, et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomono-cytic leukemia. Blood 88:2473, 1996.

20. Beran M, Estey E, O'Brien S, et al.: Results of topotecan single agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31:521, 1998.

21. Beran M, O'Brien S, Thomas DA, et al.: Phase I study of oral topotecan in hematologic malignancies. Clin Cancer Res 15:4084, 2003.

22. Grinblatt DL, Daohai Y, Klein C, et al.: Two schedules of oral topotecan for myelodysplastic syndromes (MDS)—CALGB Study 19803. Proc Am Soc Clin Oncol 20:303a, 2001. Abstract 1209.

23. Grinblatt DL, Yu D, Hars V, et al.: Relationship of response to oral topotecan (topo) for myelodysplastic syndromes (MDS) with IPSS group and cytogenetics--CALGB Study 19803. Blood 100: Abstract 3137, 2002.

24. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neopasia: pathophysiology and therapeutic implications. Ann Intern Med 134:573, 2001.

25. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 15:2429, 2002.

26. Wijermans P, Lubbert M, Verhoef G, et al.: Low-dose 5-aza-2'deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956, 2000.

27. Lubbert M, Wijermans P, Kunzmann R, et al.: Cytogenetic responses in high risk myelodysplastic syndromes following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 114:349, 2001.

28. Drucker BJ, Tamura B, Buchdunker E, et al.: Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561, 1996.

29. Issa JP, Garcia-Manero G, Giles FJ, et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycitidine (decitabine) in hematopoeitic malignancies. Blood 103:1635, 2004.

30. Garcia JL, Font de Mora J, Hermandez JM, et al.: Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 102:2699, 2003.

31. Cortes J, Giles F, O'Brien S, et al.: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97:2760, 2003.

32. Raza A, Lisak L, Dutt D, et al.: Gleevac (imatinib mesy-late) in 16 patients with chronic myelomonocytic leukemia (CMMoL). Blood 96(suppl 1): Abstract 4829, 2000.

33. Talpaz M, Silver RT, Drucker R, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928, 2002.

34. Rebollo A, Martinez AC: Ras proteins: research advances and new functions. Blood 94:2971, 1999.

35. Le DT, Shannon KM: Ras processing as a therapeutic target in hematological malignancies. Curr Opin Hematol 9:308, 2002.

36. Onida F, Gatto S, Scappini B, et al.: Significance of ras point mutations for prognosis and response to treatment in chronic myelomonocytic leukemia: analysis of 112 patients. Proc Am Soc Clin Oncol 20: Abstract 1048, 2002.

37. Kurzrock R, Sebti SM, Kantarjian HM, et al.: Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome [abstract]. Blood 98:623a, 2001.

38. Kurzrock R, Kantarjian H, Cortes JE, et al.: Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome: clinical and biological activities in the phase I setting. Blood 102:4527, 2003.

39. Gotlib J, Loh M, Vattikuti S, et al.: Phase I/II Zarnestra™ (farnesyl transferase inhibitor (FTI) R11577, Tipifarnib) in patients with myeloproliferative disorders (MPDs): preliminary results. Blood 100: Abstract 3153, 2002.

40. Feldman E, Cortes J, Holyoake T, et al.: Continuous oral lonafarnib (SarasarTM) for the treatment of patients with myelodysplastic syndrome. Blood 102: Abstract 1531, 2003.

41. Verstovsek S, Estey E, Manshouri T, et al.: Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia and myelodysplastic syndrome. Br J Haematol 188:151, 2002.

42. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958, 2001.

43. Strupp C, Germing U, Aivado M, et al.: Thalidomide treatment of patients with myelodysplastic syndromes. Leukemia 16:1, 2002.

44. Beran M, Onida F, Cortes J, et al.: Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia (CMML). Blood 98: Abstract 2614, 2001.

45. Beran M, Shen Y, Onida F, et al.: Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymph 47:417, 2006

46. Kroger N, Zabelina T, Guardiola P, et al.: Allogeneic stem cell transplantation of adult chronic myelomono-cytic leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Bone Marrow Transplantation (EBMT). Br J Haematol 118:67-73, 2002.

47. Zang DY, Deeg HJ, Gooley T, et al.: Treatment of chronic myelomonocytic leukemia by allogeneic bone marrow transplantation. Br J Haematol 110:217, 2000.

48. Locatelli F, Niemeyer CH, Angelucai E, et al.: Allogeneic bone marrow transplantation for chronic myelomono-cytic leukemia in childhood. A report from the European Working Group on Myelodysplastic Syndromes in Childhood. J Clin Oncol 15:566, 1997.

49. Cuger S, Sacks N: Bone marrow transplantation for myelodysplastic syndrome—who? when? and which? Bone Marrow Transplant 30:199, 2002.

50. Benesch M, Deeg HJ: Hematopoeitc stem cell transplantation for acute patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 78:891, 2003.

51. Maziarz RT, Mesa RA: Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndrome: the question is "when?" Mayo Clin Proc 78:941, 2003.

52. Przepiorka S, Giralt S, Khouri I, et al.: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57:24, 1998.

53. Alzea EP, Kim HT, Cutter C, et al.: AML and MDS treated with nonmyeloablative stem cell transplantation: overall and progression-free survival comparable to myeloablative transplantation. Blood 102: Abstract 266, 2003.

54. Giralt S, Anagnastopoulos A, Shahjahauau M, et al.: Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 39:57, 2002.

55. Cutler C, Lee S, Greenberg P, et al.: A decision analysis of allogeneic stem cell transplantation for MDS: delayed transition for low risk MDS is associated with improved outcome. Blood 104:579, 2002.

56. Onida F, Ball G, Kantarjian HM, et al.: Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 95:1673, 2002.

57. Pugh WC, Pearson M, Vardiman JW, et al.: Philadelphia chromosome-negative chronic myelogenous leukaemia: a morphological reassessment. Br J Haematol 60:457, 1985.

58. Kantarjian HM, Keating MJ, Walkers RS, et al.: Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58:2023, 1986.61. Costello R, Sainty D, Lafage-Pochitaloff M, et al.: Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma 25:225, 1997.

59. Martiat P, Michaux JL, Rodhain J: Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood 78:205, 1991.

60. Cortes J, O'Brien S, Beran M, et al.: Efficacy of a topoi-somerase I inhibitor, 9-nitro-20-(S)-camptothecin (9-NC, RFS2000) in chronic myelomonocytic leukemia (CMML) and high-risk myelodysplastic syndromes (MDS). Blood 98: Abstract 2602, 2001.

61. Kantarjian HM, Shtalrid M, Kurzrock R, et al.: Significance and correlations of molecular analysis result in patients with Philadelphia-chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med 85:639, 1988.

62. Spiers ASD: Management of the chronic leukemias: special considerations in the elderly patient. Part III: Rarer chronic myeloid leukemias. Hematology 7:1, 2002.

63. Kurzrock R, Kantarjian H, Shtalrid M, et al.: Philadelphia chromosome-negative chronic myeloge-nous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 75:445, 1990.

64. Steensma DP, Tefferi A, Li CY: Clinical outcomes and pathological patterns after splenectomy for chronic myelomonocytic leukemia (CMML). Blood 102: Abstract 4907, 2003.

65. Benesch M, Deeg HJ: Hematopoeitic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 78:981, 2003.

66. Schaller JL, Burkland GA: Case report: rapid and complete control of idiopathic hypereosinophilia with ima-tinib mesylate. Med Gen Med 3:9, 2001.

67. Ault P, Cortes J, Koller C, et al.: Response of idiopathic hypereosinophilic syndrome to treatment with ima-tinib mesylate. Leuk Res 26:881, 2002.

68. Cortes J, Ault P, Koller C, et al.: Efficacy of imatinib mesylate in the treatment of idiopathic hypere-osinophilic syndrome. Blood 101:4714, 2003.

69. Cools J, De Angelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201, 2003.

70. Salem Z, Zalloua PA, Chehal A, et al.: Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J 4:410, 2003.

71. Klion AD, Robyn J, Akin C, et al.: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloprolifer-ative variant of hypereosinophilic syndrome. Blood 103:473, 2004.

72. Pitini V, Arrigo C, Azzarello D, et al.: Serum concentration of cardiac troponin T in patients with hypere-osinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 102:3456, 2003.

73. Griffin JH, Leung J, Bruner RJ, et al.: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 100:7830, 2003.

74. Cools J, Stover EH, Boulton CL, et al.: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3:4509, 2003.

75. Brito-Babapulle, F: The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 121:203-233, 2003.

76. Bain B, Pierre R, Imbert M, et al.: Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.) Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: World Health Organization of Tumours, IARC Press; 2001:29.

77. Oliver JW, Deol I, Morgan DL, et al.: Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review and report of a case with unique chromosomal abnormality. Cancer Genet Cytogenet 107:111-117, 1998.

78. Chusid MJ, Dale DC, West BC, et al.: The hypere-osinophilic syndrome: analysis of fourteen cases and review of the literature. Medicine 54:1, 1975.

79. Brito-Babapulle E: Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev 11:129-145, 1997.

80. Roufosse F, Cogan E, Goldman M: The hypereosinophilic syndrome revisited. Ann Rev Med 54:169, 2003.

81. Cogan E, Schandene L, Crusiaux A, et al.: Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Eng J Med 330:535, 1994.

82. Simon HU, Yousefi S, Dommann-Scherrer CC, et al.: Expansion of cytokine-producing CD4-DC8-T cells associated with abnormal Fas expression and hypere-osinophilia. J Exp Med 183:1071, 1996.

83. Simon HU, Plotz SG, Dummer R, et al.: Abnormal clones of T-cells producing interleukin 5 in idiopathic hypereosinophilia. N Engl J Med 341:1112, 1999.

84. Pardanani A, Elliott M, Reeder T, et al.: Imatinib for systemic mast-cell disease. Lancet 362:535, 2003.

85. Pottier P, Planchon B, Grossi O: Complete remission with imatinib mesylate (Glivec) of an idiopathic hyper-eosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha. Rev Med Interne 24:542, 2003.

86. Klion AD, Noel P, Akin C et al.: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypere-osinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib responsiveness. Blood 101:4660-4666, 2003.

87. Ommen SR, Seward JB, Tajik AJ: Clinical and echocar-diographic features of the hypereosinophilic syndrome. Am J Cardiol 86:110, 2000.

88. Hayashi S, Isobe M, Okubo Y, et al.: Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens. Heart Vessels 14:104, 1999.

89. Fauci AS, Harley JB, Roberts WC, et al.: NIH Conference: the idiopathic hypereosinophilic syndromes. Clinical, pathophysiological and therapeutic considerations. Ann Intern Med 97:78, 1982.

90. Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood 83:2759, 1994.

91. Parillo JE, Fauci AS, Wolff SM: Therapy of the hypereosinophilic syndrome. Ann Intern Med 89:167, 1978.

92. Lee JH, Lee JW, Jang CS, et al.: Successful cyclophos-phamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome. Yonsei Med J 43:267, 2002.

93. Cofrancesco E, Cortellaro M, Pogliani E, et al.: Response to vincristine treatment in a case of idiopathic hypere-osinophilic syndrome with multiple clinical manifestations. Acta Haematol 72:21, 1984.

94. Sakamoto K, Erdreich-Epstein A, deClerck Y, et al.: Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 14:348, 1992.

95. Nadarajah S, Krafchick B, Roifman C, et al.: Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T cell abnormality. Paediatrics 99:630, 1997.

96. Zabel P, Schlaak M: Cyclosporin for hypereosinophilic syndrome. Ann Hematol 62:230, 1991.

97. Ueno NT, Zhao S, Robertson LE, et al.: 2 Chlorodeoxyadenosive therapy for idopathic hypere-osinophilic syndrome. Leukaemia 11:1386, 1997.

98. Kantarjian HM, Smith TL, O'Brien S, et al.: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 122:254, 1995.

99. Butterfield JH, Gelich GJ: Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J Allergy Clin Immunol 94:1318, 1994.

100. Baratta L, Afeltra A, Delfino M, et al.: Favorable response to high-dose interferon-alpha in idiopathic hypere-osinophilic syndrome with restrictive cardiomyopa-thy—case report and literature review. Angiology 53:465, 2002.

101. Luciano L, Catalano L, Sarrantonio C, et al.: AlphalNF-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 84:651, 1999.

102. Ceretelli S, Capochiani E, Petrini M: Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 77:161, 1998.

103. Canonica GW, Passalacqua G, Pronzato C, et al.: Effective long term alpha interferon treatment for hypereosinophilic syndrome. J Allergy Clin Immunol 96:131, 1995.

104. Schoffski P, Ganser A, Pascheberg U, et al.: Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol 79:95, 2000.

105. Yamada O, Kitahara K, Imamura K, et al.: Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukaemia associated with a unique t(3:9:5) translocation. Am J Haematol 58:137, 1998.

106. Malbrain ML, Van den Bergh H, Zachee P: Further evidence for the clonal nature of the idiopathic hypere-osinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 92:176, 1996.

107. Zielinski RM, Lawrence WD: Interferon a for the hypereosinophilic syndrome. Ann Intern Med 113:716, 1990.

108. Pardanani A, Reeder T, Porrata LF, et al.: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391, 2003.

109. Gotlib J, Cools J, Malone JM lll, et al.: The FlP1L1-PAGFRalpha fusion tyrosine kinase in hypere-osinophilic syndromes and chronic eosinophilic leukemia: implications for diagnosis, classification and management. Blood 103:2879, 2004.

110. Pardanani A, Ketterlin RP, Brockman SR, et al.: CHlC2 deletion, a surrogate for FlP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093, 2003.

111. Kantarjian HM, Sawyers CL, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645, 2002.

112. Cortes J, Giles F, O'Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia-positive chronic myelogenous leukemia after failure to interferon-a. Blood 102:83, 2003.

113. Quintas-Cardama A, Tefferi A, Corter J, et al.: Alemtuzumab (Campath-1HTM) is effective therapy for hypereosinophilic syndrome (HES). Submitted to ASH, abstract, 2006.

114. Vazquez L, Caballero D, Canizo DC, et al.: Allogeneic peripheral blood cell transplantation for hypere-osinophilic syndrome with myelofibrosis. Bone Marrow Transplant 25:217, 2000.

115. Chockalingam A, Jalil A, Shadduck RK, et al.: Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 23:1093, 1999.

116. Fukushima T, Kuriyama K, lto H, et al.: Successful bone marrow transplantation for idiopathic hypere-osinophilic syndrome. Br J Haematol 90:213, 1995.

117. Sadoun A, Lacotte L, Delwail V, et al.: Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 19:741, 1997.

118. Juvonen E, Volin L, Kopenen A, et al.: Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 29:457, 2002.

119. Ueno NT, Anagnostopoulos A, Rondon G, et al.: Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119:131, 2002.

Was this article helpful?

0 0

Post a comment